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Abstract 
Organic anion transporting polypeptides (OATPs) are polyspecific organic anion 
transporters, which are expressed in the blood brain barrier, the choroid plexus and other 
organs. The physiologic function of OATPs in extrahepatic tissues remains ambiguous. 
In rat retina, members of the OATP family are expressed. We therefore investigated the 
human retina for the expression of OATP1A2 and OATP2B1 and extend the study to 
human brain. Furthermore, we searched for peptide neurotransmitters as novel OATP 
substrates. OATP1A2 displayed a broad expression pattern in human retina as assessed 
by immunofluorescence localization in fixed-frozen section. It is expressed in 
photoreceptor bodies and somas of amacrine cells. OATP1B2 expression is restricted to 
the inner nuclear layer and to the inner plexiform layer. Using paraffin sections from 
human cortex, cerebellum and hippocampus, OATP1A2 was localized to neurons and 
neuronal processes, while OATP2B1 is expressed in endothelial cells of brain capillaries. 
Substance P and vasoactive intestinal peptide were identified as substrates for OATP1A2 
and OATP2B1. Double-labeling immunofluorescence of human retina demonstrated the 
presence of substance P and of vasoactive intestinal peptides in neurons, which express 
OATP1A2 and OATP2B1, respectively. Our data suggest first that OATP1A2 and 
OATP2B1 may be involved in the reuptake of peptide neurotransmitters release from 
retinal neurons. Second, the abundant expression of OATP1A2 in brain neurons points to 
the possibility that OATP1A2 could be involved in the homeostasis of neurosteroids. 
Third, the high expression of OATP2B1 of in brain capillaries supports an important 
function of OATPs in substance penetration across the blood brain barrier. 
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Introduction 
Organic anion transporting polypeptides (humans OATPs, rodents rOATPs), 
represent an important group of transporters with a wide spectrum of amphipathic 
substrates [17, 27]. Initially, OATPs were isolated from liver and localized to the 
basolateral membrane of hepatocytes, where they mediate sodium-independent transport 
of bile salts and cholephilic anionic compounds. To date dozens of family members, 
including 16 in rat, 15 in mouse and 11 in human, have been identified. They are 
expressed in many organs including kidney, placenta, brain and retina [16, 18, 27]. 
Besides bile salts, they transport a wide range of endogenous and exogenous compounds, 
such as steroid hormones and their conjugates, thyroid hormones, prostaglandins, small 
peptides and numerous drugs. [16, 18] Yet, physiological functions of these transporters 
in extrahepatic organs remain ambiguous. Since many members are expressed in cells 
that constitute barriers limiting the exchange of solutes between compartments, e.g. blood 
brain barrier, choroid plexus epithelium and testis, it is believed that OATPs play a role 
in maintaining tissue homeostasis, bioavailability and disposition of numerous drugs [16, 
25, 56]. 
In rat retina, Oatp1a4 and Oatp1a5 have been identified. Oatp1a4 has been 
localized in the apical region of the retinal pigment epithelium (RPE) [9] and Oatp1a5 in 
the ganglion and inner nuclear cell layers [24]. Although their distinct functions in the 
retina remain to be established, evidence that Oatp1a4-mediated transport activities could 
be competitively inhibited by the N-retinyl-N-retinylidene ethanolamine, an unusual 
retinoid implicated in the age-related visual impairment [53], suggests that this 
transporter is involved in accumulating this harmful retinoid in the RPE [9]. Despite their 
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potential significance in retinal pathogenesis, it is so far not clear whether OATPs are 
expressed in human retina. 
Therefore, we aimed to investigate the expression of OATPs in human retina. We 
analyzed OATP1A2 and OATP2B1 in the present study, as they are very likely expressed 
in the retina for several reasons. First, OATP1A2 is classified with Oatp1a4 and Oatp1a5 
in Oatp1a/OATP1A subfamily [17] and thus closely related to the rat Oatps expressed in 
the retina. Second, these two OATPs are abundantly expressed in the brain [29, 30]. It is 
well known that many brain-expressed neurotransmitter transporters are also expressed in 
retina [3]. Finally, OATP1A2 and OATP2B1 display strong expression in the ocular 
ciliary body epithelium [8], a tissue with which retina is anatomically connected and has 
a common embryonic origin. Previously, we have reported the expression of OATP1A2 
in brain capillary endothelium [7], but the cellular localization of OATP2B1 was not 
determined. Given the expression of neurotransmitter transporters in retina and in brain, 
we included human brain into the localization studies. Finally, we searched for 
physiologic substrates pertinent to the cell type specific expression of OATP1A2 and 
OATP2B1. 
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Materials and Methods 
Antibodies 
Polyclonal affinity purified OATP1A2 and OATP2B1 were generated in rabbits 
and characterized as previously described [7, 8, 22, 30] Guinea pig anti-substance P (SP) 
and sheep anti-vasoactive intestinal peptide (VIP) were purchased from Chemicon 
(Temecula, CA, USA). All secondary antibodies conjugated with either Cy2 or Cy3 
fluorochrome and with biotin-horseradish peroxidase were purchased from Jackson 
Immunoresearch (West Grove, PA, USA) and Santa Cruz (Santa Cruz, CA, USA), 
respectively. 
Chemicals 
3
H-labeled SP was purchased from PerkinElmer Life Sciences, Inc (Boston, MA, 
USA), and 
125
I-labeled somatostatin, VIP and neuropeptide Y (NPY) were from 
Amersham Bioscience (Buckinghamshire, England). Unlabeled SP and VIP were from 
Bachem (Basel, Switzerland). All other chemicals were obtained from Fluka (Buchs, 
Switzerland), Merck (Whitehouse Station, NJ, USA) and Sigma Chemicals (St. Louis, 
MO, USA) at the highest purity available. 
Human tissue collections 
Retinas were collected from four deceased patients of both genders (age range: 
25-88 years) during routine autopsies (post-mortem periods: 8 – 12 hours) in the 
Department of Ophthalmology, University Hospital Zurich, according to a protocol 
approved by the local Ethics Committee. One of these retinas was used for immunoblot 
analysis, thus frozen immediately in liquid nitrogen upon dissection. The other retinas 
were fixed as described below for immunofluorescence staining experiments. Human 5 
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μm brain sections embedded in paraffin were provided by the Department of 
Neuropathology, University Hospital Zürich. They were cut from the frontal cerebral 
cortex and the hippocampal formation. These specimens were from two patients (both 
genders, aged 39- and 79-year-old) without evidence of neurological or psychiatric 
disorders and with normal brain morphology. The post-mortem intervals were 30 - 48 
hours. The blocks of the specimens were fixed routinely with formalin after removal 
during autopsy.  
Immunoblot analysis 
The isolated human retina was processed as described in[9]. In brief, it was 
homogenized in 100 mM Tris pH 7.5 with a tip sonicator and the homogenates were 
centrifuged at 1000 x g for 5 minutes to remove large debris. Protein content of the 
supernatant was assessed by the Bradford assay (BioRad, Hercules, CA) using BSA as 
standard. The supernatant was mixed with SDS sample buffer, heated to 70°C for 10 
minutes and stored at – 20° until use. Proteins were separated on 7.5% SDS-
polyacrylamide gels and transferred to nitrocellulose membranes. Blots were blocked for 
1 hr at room temperature in 10 mM Tris/HCl (pH 8.0), 150 mM NaCl, and 0.05% (w/v) 
Tween (TBST) containing 5 % (w/v) blocker (nonfat dry milk, Bio-Rad) and incubated 
overnight at 4°C with primary antibodies in TBST containing 5% (w/v) blocker. After 
rinsing, blots were incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG 
diluted at 1:5000 for 1 hr at room temperature and immunoreactivity was visualized with 
the Renaissance Western blot detection kit (NEN Life Science products, Boston, MA, 
USA). 
Immunofluorescence staining 
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Dissected retinas were fixed in phosphate-buffered saline (PBS) containing 3% 
(w/v) paraformaldehyde and 0.1% (w/v) glutaraldehyde (pH 7.4) at 4ºC for 2 hours, 
cryoprotected in 30% (w/v) sucrose overnight at 4ºC, embedded in M1-embedding matrix 
(Lipshaw, Pittsburg, PA, USA) and stored at –70°C until use. 
10 µm vertical cryostat sections were cut and mounted on glass slides coated with 
0.5% gelatin and incubated with primary antibodies in phosphate saline buffer (PBS) 
containing 2% (v/v) normal goat serum and 0.2% (w/v) Triton X-100 overnight at 4ºC. 
The dilution for OATP1A2 was 3μg/ml and for OATP2B1 1μg/ml. Sections were washed 
three times with PBS and incubated for 30 minutes at room temperature with the Cy3-
conjugated goat anti-rabbit antibody (1:300) diluted in the same buffer as for the primary 
antibody incubation. Subsequently sections were washed several times with PBS and 
coverslipped with Immu-mount (Shandon, Pittsburgh, PA, USA). For double staining 
experiments, sections were coincubated one of the OATP antibodies with either anti-SP 
or anti-VIP. The signal for OATP1A2 and OATP2B1 was detected with the Cy3-
conjugated goat anti-rabbit antibody (1:300), and for SP and VIP was with a Cy2-
conjugated goat antibody against corresponding species. 
Immunoperoxidase staining 
 Because of the very high level of autofluorescence on human brain sections, 
immunoperoxidase staining was used to detect signals in the brain specimens. The 
sections were first dewaxed with xylone and hydrated by passing through descending 
serial ethanol solutions, then treated with 0.1M hydrochloride acid for 10 min, 0.1% 
(w/v) saponin in PBS for 30 min and finally with 1.5% (w/v) hydrogen peroxide for 10 
min to eliminate endogenous peroxidase activivity.  For antigen-retrieval, sections were 
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 9 
immersed in 0.2 M citric acid (pH 4.5) and heated 3 times to 80°C for 5 min in a 
microwave processor. In initial experiments sections were heated for 1, 3 and 5 times in 
order to optimize detection, and 3 times of microwave radiation was found suitable for 
the present study. Afterwards sections were incubated overnight at 4ºC with antibodies to 
OATP1A2 (10μg/ml) or OATP2B1 (3μg/ml) diluted in 50 mM Tris/100 mM NaCl (Tris-
saline, pH 7.4) containing 2% (w/v) normal goat serum and 0.05% (w/v) Triton X-100. 
They were washed in Tris-saline and stained by the ABC-immunoperoxidase method 
with Vectastain Elite kit (Vector Laboratories, Burlingame, CA, USA) and 
diaminobenzidine hydrochloride as chromogen. Finally, sections were dehydrated with 
ascending series of ethanol, and coversplipped out of xylene. Negative control 
experiments in which sections were incubated with the primary antibody preabsorbed 
with 5-10mg/ml of corresponding peptides used for immunization were carried out to 
verify the specificity of the positive signal. After processing. sections were analyzed by 
confocal laser microscopy (MRC 600 confocal imaging system, BioRad Laboratories, 
Richmont, CA) using a Zeiss Axioplan microscope (Oberkochen, Germany). 
Transport assays in Xenopus laevis oocytes 
Mature X. laevis females were purchased from the African Xenopus facility 
(Noordhoek, Republic of South Africa) and kept under standard conditions. The animals 
received human care according to federal and local regulations and the experiments were 
approved by the local government’s animal care committee. In vitro synthesis of cRNAs 
for OATP1A2 and OATP2B1 was performed from the respective cDNAs as described 
[29, 30].  
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Oocytes were prepared and as previously described [44]. Healthy oocytes were 
microinjected with either water (control) or 5ng of cRNA encoding OATP1A2 or 
OATP2B1. The oocytes were cultured for three days to allow expression of the 
transporter proteins. Tracer uptake experiments were carried out in the presence of Na
+
 
(100 mM NaCl) or absence of Na
+
 (100 mM choline chloride) in uptake media containing 
2 mM KCl, 1 mM CaCl2, 1mM MgCl2, and 10 mM HEPES/Tris (pH 7.5). Fifteen 
oocytes were prewashed in the uptake medium and then incubated at 25 °C in 100 μl of 
uptake medium supplemented with radiolabeled and unlabeled compounds. 
Subsequently, oocytes were washed 3 times with 6 ml of ice-cold incubation buffer 
without radiolabelled substrate and single oocytes were dissolved in 10% SDS. After 
addition of 5 ml of scintillation fluid (Ultima Gold; Canberra Industries, Meriden, CT), 
the oocyte-associated radioactivity was measured in a Packard Tri-Carb 2200 CA liquid 
scintillation analyzer (Canberra Industries). Statistical significance was calculated with 
the unpaired Student's t-test (Systat, SPSS, Chicago IL). Km values were estimated by 
non-linear regression analysis using the Michaelis-Menten model with Systat. Uptake 
values into transporter expressing oocytes were corrected for uptake into water injected 
oocytes. 
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Results 
Expression of the OATP1A2- and OATP2B1-immunoreactivity in the human 
retina 
Immunofluorescence microscopy analysis of retina sections demonstrated that 
both antibodies displayed strongly reactivity (Fig 1A and 2A). Surprisingly however, no 
immunoreactivity was observed in the apical region of the retina pigment epithelium, the 
site at which Oatp1a4 immunoreactivity is located in rat retina [9]. OATP1A2 
immunoreactivity appeared broadly in many retina cell layers, including the outer nuclear 
layer (ONL), inner nuclear layer (INL), inner plexiform layer (IPL) and the ganglion cell 
layer (GCL) (Fig 1A). At high magnification, the staining in the ONL was seen at the 
plasma membrane of photoreceptor bodies (Fig. 1C). In the INL, OATP1A2 
immunjoreactivity was abundant in many cell somas that are lying in the innermost part 
of the layer, resembling amacrine neurons. These cells were often seen to extend their 
strongly stained processes into the IPL and GCL (Fig. 1 E). In the GCL, a few small cells 
were also stained, whereas large ganglion cells appeared negative (Fig. 1E and Fig 6A). 
For OATP2B1, the staining was rather restricted to the innermost part of the INL and in 
the IPL (Fig. 2A). At high magnification, the OATP2B1-IR in the INL was present in 
proximal processes of amacrine cells, but sparsely in their somas (Fig. 2C, Fig. 6B and 
Fig. 7B). In the IPL, numerous neuronal processes were stained, forming a dense plexus 
of OATP2B1 immunoreactivity throughout the entire layer (Fig. 2A and 2C). 
In control experiments in which adjacent sections were incubated with antibodies 
preabsorbed with the corresponding peptide antigens used for immunization, no positive 
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signals were detected (Fig. 1B and 2B), whereby the faint reaction in the RPE is due to 
autofluorescence of the tissue. 
Western blot experiments were carried out to further confirm the presence of 
OATP1A2 and OATP2B1 proteins in the retina. As illustrated in Fig. 3, both antibodies 
reacted specifically with retina homogenates. OATP1A2 and OATP2B1 proteins in the 
retina appear to have a similar size (~70-80 kDa) to that identified in the liver, placenta, 
and ciliary body [8, 30, 48]. 
OATP1A2- and OATP2B1-mediated transport activities of bioactive peptides in 
Xenopus laevis oocytes 
The findings that OATP1A2 and OATP2B1 are present in the retina amacrine 
neurons prompted us to assume that these transporters may play a role in mediating 
transport of some neuronal messengers, such as neurotransmitters or neuroactive 
peptides. While previous data have indicated that neurotransmitters, such as GABA, 
glutamine and serotonin, are most likely not substrates of rat Oatps [40], it is not clear, 
however, whether this assumption also holds true for human OATPs. Human amacrine 
neurons are known for containing several neurotransmitters such as GABA, dopamine, 
glycine and glutamate [5, 43], and many bioactive peptides, including SP, VIP, 
somatostatin (SOM) and NPY [6, 33, 39, 49, 54]. To corroborate our hypothesis that 
OATP1A2 and OATP2B1 may mediate transport of some of the neuroactive substances, 
functional transport assays were performed in OATP-expressing oocytes. Not 
surprisingly, no transport activities were found for neurotransmitters GABA, glutamate, 
glycine and dopamine (not shown) in these experiments. However, compared with water-
injected oocytes OATP1A2- and OATP2B1-expressing oocytes exhibited 2-3 fold uptake 
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signals for SP and VIP, but not for SOM and NPY (Fig. 4). Further analysis indicated 
that OATP1A2- and OATP2B1-mediated uptake for SP and VIP was sodium-
independent (Fig. 4A and B) and saturable with apparent Km-values of 76 M and 73 
M for OATP1A2-mediated SP and VIP uptake and 84 M and 94 M for OATP2B1-
mediated SP and VIP uptake, respectively (Fig. 5). 
Expression of the OATP1A2- and OATP2B1-IR in retina SP- and VIP-containing 
neurons 
It is well known that neurotransmitter transporters are often expressed in the same 
neurons that release corresponding neurotransmitters in order to take up again released 
neurotransmitters back into neurons. Since OATP1A2 and OATP2B1 exhibit transport 
activities for SP and VIP, we investigated whether OATP1A2 and OATP2B1 are 
expressed in subpopulations of amacrine cells that contain SP and VIP [6, 33, 54]. 
Double fluorescence staining experiments with antibodies against OATPs and against SP 
and VIP showed extensive colocalization of OATP1A2 immunoreactivity with SP 
labelling, both in amacrine cell somas in the INL and in neurites of the IPL and GCL 
(Fig. 6A). A few SP-containing cells in GCL, previously identified as SP-containing 
amacrine cells [2, 19, 60], were also labeled with OATP1A2 (Fig. 6A). OATP1A2 
immunoreactivity was also colocalized with VIP fluorescence, particularly in the small 
cells and neurites in the GCL, but less in the IPL and INL (Fig.7A). OATP2B1 
immunoreactivity was, although to a lesser extent, also colocalized with SP labeling, 
especially at neuronal processes in the IPL (Fig. 6B). When the OATP2B1 antibody was 
coincubated with the VIP antibody, the OATP2B1 immunoreactive neuronal processes 
were intensely colocalized with VIP fluorescence (Fig. 7B). 
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In addition, to clarify whether the abundant OATP immunoreactivity in the GCL 
(Fig. 1A) is also present in retinal macroglial cells (astrocytes and Müller cells) localized 
in this layer [58], double staining experiments were performed in which the anti-
OATP1A2 antibody was coincubated with an anti-glial fibrillary acidic protein, a glial 
marker. No colocalization of the OATP1A2-IR with the glia cell marker was found in 
these experiments (not shown). 
Localization of OATP1A2 and OATP2B1 in the human frontal cortex and 
hippocampus 
Expression of OATP1A2 and OATP2B1 in the retina neurons raises the 
possibility that the two OATPs may be also expressed in brain neurons. We have 
previously detected a weak, but distinct expression of the OATP1A2 immunoreactivity in 
brain capillary endothelial cells on fresh cryostat sections of the cerebral cortex [7], while 
on Northern blots OATP1A2 is abundantly expressed in human brain [29]. Mildly fixed 
cryostat sections, although perhaps good for detection of some antigens, usually have 
poorly preserved the plasma membrane structure, thus may not be very suitable for 
recognizing proteins associated neuronal processes. In the present study we used paraffin 
embedded sections and applied a microwave antigen-retrieval protocol. With this 
protocol OATP1A2 was found to be abundantly expressed in neurons in both, cortex and 
hippocampus (Fig. 8 and 9). As illustrated in Fig. 8A, in the frontal cortex neurons 
scattered all layers were labeled with the OATP1A2 immunoreactivity. In the 
hippocampal formation, shown in Fig. 9, pyramidal neurons in the CA1and CA2 region 
and granule cells in the dentate gyrus were also strongly labeled. Under high 
magnification, the OATP1A2 immunoreactivity was associated with the plasma 
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membrane of cell somas and with neuronal processes (Fig. 8C, 9B and C). Consistent 
with the previous finding [7], OATP1A2 immunoreactivity was also occasionally found 
in capillary endothelial cells (Fig. 8A and C) in the paraffin sections used for this study. 
Surprisingly though, the OATP2B1 immunoreactivity was distinctly associated 
with brain capillary endothelial cells (Fig. 10) in both brain regions examined. The 
staining was clearly associated with the plasma membrane of the endothelium under high 
magnification (Fig. 10C). OATP2B1 immunoreactivity associated endothelial cells were 
numerous in both the cortex and hippocampus. The abundant expression of OATP2B1 in 
capillary endothelial cells suggests that this transporter plays an important role at the 
BBB. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 16 
Discussion 
The data presented here show: (1) OATP1A21 and OATP2B1 are abundantly 
expressed in retina SP- and VIP- containing amacrine neurons and their processes; (2) 
OATP1A2 and OATP2B1 exhibit transport activities for SP and VIP when expressed in 
X. laevis oocytes; (3) in the cerebral cortex and hippocampal formation OATP1A2 is 
predominantly present in various types of neurons and OATP2B1 exclusively in the 
blood-brain barrier. 
The diversity of cellular distribution of OATP1A2 and OATP2B2 in the CNS is 
somewhat surprising. This diversity is reflected not only in different cell types, but also in 
various types of neurons with distinct neurotransmitter phenotypes. For example, 
OATP2B1 in retina is distinctly present in amacrine neurons (Fig. 2), whereas in the 
brain it localizes to the capillary endothelium (Fig. 10). OATP1A2 is expressed in 
amacrine cells (Fig. 1) that contain inhibitory neurotransmitters, e.g. GABA [5], and also 
in neurons containing the excitatory neurotransmitter glutamate, such as photoreceptor 
cells, hippocampal pyramidal and granule cells [1, 5]. It was previously noted in rat that 
the retina utilizes different mechanisms from the brain for regulating the expression of 
transporters. For example, the glycin transporter Glyt1 is expressed in glia cells of rat 
brain and in amacrine cells in the retina [59]. In humans, Glyt-1 expression is absent in 
Müller cells of intact retina, but present in cultured Müller cells [45]. Similarly, while the 
glutamate transporter GLT-1 is located in brain in glial cells, it is found neurons of the 
retina [52]. So far, the knowledge about factors involved in determining the differential 
cellular expression of such transporters is still in its infancy [10, 45]. Our findings of the 
OATP2B1 localization to distinct cells in brain and retina are another example of 
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differential regulation of transporter expression in the CNS [45] The highly 
heterogeneous cellular distribution and their multispecific transport properties [16] 
indicate complex functions of OATP1A2 and OATP2B1 in the CNS.  
In the present study we have identified the neuropeptides SP (11 amino acids) and 
VIP (28 amino acids) as substrates of OATP1A2 and OATP2B1. This result is not 
unexpected since Oatps/OATPs seem to have preferences for small peptides with 10-20 
amino acids [16]. Our data, however, do not definitively proof that OATPs function as 
peptide uptake systems in the CNS as do they do for example in liver [23] or across BBB 
[7]. Neuropeptides, stored in synaptic vesicles, are often released together with 
neurotransmitters by presynaptic neurons. Unlike neurotransmitters that are mostly 
recycled back to neurons by their corresponding transporters, elimination of neuroactive 
peptides from the synaptic cleft is generally thought by diffusion and, more importantly, 
by degradation with peptidases. Of several enzymes that are involved in metabolizing SP 
and VIP [4, 21, 36], neutral endopeptidase (NEP, EC. 3.4.24.11) appears to play a 
predominant role in the brain [11, 12, 20, 21, 38, 55]. This enzyme is abundantly present 
in the striatonigral pathway but scarcely, if at all, in the cerebral cortex (100% vs. 4%) 
[38]. Thus, NEP distribution seems to be only matched, notably in striatonigral pathway, 
with that of SP, but not in the cerebral cortex where both SP- and VIP- containing 
neurons and their processes are abundantly located [34, 35]. This only partially matched 
distribution pattern was also demonstrated in a detailed immunohistochemistry analysis 
[37]. There is no report so far, to our knowledge, on the presence of NPE in the retina. 
Another peptidase angiotensin-converting enzyme (3.4.15.1) is also suggested to be 
involved in inactivation of SP in the brain [21, 51]. It has a very low capacity compared 
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to that of NEP [21], and is also mainly present in the striatonigral pathway [51]. In the 
retina angiotensin converting enzyme was only detected in chicken after pretreatment 
with protease inhibitors [57], but not in the rat [50], suggesting a at best a low expression 
level in this tissue. Taken together, the partially matched distribution pattern raises a 
possibility that alternative mechanism(s) may be involved in determining turning over the 
released neuroactive peptides in the synaptic cleft, particularly in areas that are short of 
degrading enzymes but rich in peptides, such as the cerebral cortex [34, 35, 47] and 
retina. Our findings that OATP1A2 and OAPT2B1 are abundantly present in the cerebral 
cortex and retina, and that they exhibit saturable transport activity for SP and VIP argue 
for a functional role of these OATPs in clearing released neuropeptides. Their rather low 
affinities (Km ~ 70-100μM) for these peptides appear to be in agreement with the 
generally prolonged actions of neuroactive peptides. Moreover, expression of these 
transporters in peptide-containing neurons (Fig. 6 and 7) suggests that these transporters 
may reuptake these neuroactive peptides back to the neurons as do neurotransmitter 
transporters. In this context, it is interesting to note that the amacrine cell of retina is a 
special type of nerve cells lacking an axon but their dendrites functioning as "axon-like" 
processes. Extensive expression of OATP1A2 and OATP2B1 in peptide-containing 
processes in the IPL (Fig. 6 and 7) thus suggests that uptake activity, at least in the retina, 
may occur at peptide-releasing sites. 
OATP1A2 and OATP2B1 may also mediate transport of other neuroactive 
substances in the CNS, as suggested by their broad substrate specificity and diverse 
cellular expression pattern. Of these, neurosteriods and their sulfate conjugates are of 
particular interest. OATP1A2 exhibits a very high transport activity for 
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dehydroepiandrosterone sulfate (DHEAS, Km ~ 6 μM) and estrone-3-sulfate (E3S) [28, 
30]. For OATP2B1 these two steroids, together with pregneneolone sulfate (PREGS) 
[13], are essentially the only natural substrates identified so far [16]. Functionally, steroid 
hormones are originally thought to regulate by binding to intracellular steroid receptors 
gene expression and translational processes within cells and hence exerting genomic 
effects. Substantial evidence has also accumulated indicating that some steroids, such as 
pregenolone, dehydroepianderosterone, 17-β-estradiol (both unsulfated and sulfated 
forms), can modulate neurotransmission by acting directly on neurotransmitter receptors 
such as NMDA and GABA receptors on the cell surface, thus functioning as an important 
group of neuromessengers and hence exert non-genomic effects [46]. It was believed that 
brain steroids were only supplied by blood circulation from the peripheral organs such as 
adrenal glands and gonads. Several studies have recently demonstrated that the 
machinery for synthesizing these neuroactive stereroids and their sulfate esters is present 
in brain and retina [14, 15, 31]. Pyramidal and granule neurons in the hippocampal 
formation [26] and ganglion neurons in the retina [14] appear to be the primary 
synthesizing sites in the two tissues. Thus, abundant expression of OATP1A2 on the 
surface of these cells (Fig 1 and 9), together with its transport activity for neurosteroids, 
is very intriguing. It is not clear how neurons release neurosteroids produced at the 
endoplasmic reticulum and mitochodria and how they are eliminated from the synaptic 
cleft [41, 42]. According to a current model, newly synthesized neuroactive steroids 
present in the cytosol diffuse slowly across the plasma membrane to reach target 
receptors or may diffuse within the membrane laterally to their target [41]. These 
proposed mechanisms are very different from neurotransmitters and neuroactive 
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neuropeptides that are packed into synaptic vesicles and released via exocytosis upon 
presynaptic membrane excitation. Although it is not known whether (a) transport 
system(s) is involved in this process one can assume that OATP1A2, resided at the 
plasma membrane of the hippocampal pyramidal and granule cells and exhibiting high 
transport activities for the neuroactive steroids, may facilitate transport of these 
amphipathic substances across the plasma membrane. OATP2B1, localized on the nearby 
capillary endothelial cells (Fig. 10), on the other hand, may transport these steroids out of 
releasing sites. Moreover, since Oatps/OATPs-mediated transport appear to be 
bidirectional [32], OATP2A1 may also play a role in reuptake of these substances back to 
the cell and OATP2B1 in delivering blood-borne steroids to target sites. 
In conclusion, our data suggest thatOATP1A2 and OATP2B1 are involved in 
mediating transport of neuropeptides and neurosteroids across the plasma membrane of 
neurons and capillary endothelium. Further characterization of these transporters in vivo 
is essential to clarify the data from the present study. Furthermore, the significance of 
these OATPs in mediating transport of other endogenous substances including 
prostaglandins, and in bioavailability and disposition of drugs in the CNS need to be 
explored in future. 
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Figure Legends 
Fig. 1 Expression of OATP1A2 in human retina 
 
A: Overview of immunolabelling at low magnification shows strong 
immunoreactivity for OATP1A2 in the outer nuclear layer (ONL), inner nuclear layer 
(INL) and ganglion cell layer (GCL) and weak labeling of the inner plexiform laer (IPL). 
B: Negative control with preabsorption of the antibody with the immunizing peptide 
displays some autofluorescence in the retina pigment epithelium (RPE). C: High 
magnification centered on the ONL show plasma membrane labeling of retina 
photoreceptor bodies. scale bar: 60 M D: Corresponding differential interference 
contrast (DIC) image to section C. scale bar: 12 M E: High magnification of the IPL 
demonstrates immunoreactivity of INL, IPL, and GCL. Note that stained amacrine cells 
(marked with an asterisk) extend their heavily labeled processes to the IPL and GCL. F: 
Corresponding DIC image to section E. scale bar: 10 M 
 
Fig. 2 Expression of OATP2B1 in human retina 
A: Overview of immunolabelling at low magnification shows strong 
immunoreactivity for OATP2B1 in the inner part of INL and of IPL. For orientation, the 
choroid is labeled with Ch. B: Negative control with preabsorption of the antibody with 
the immunizing peptide displays some autofluorescence in the RPE. scale bar: 55 M C: 
High magnification centered around INL with the corresponding DIC image (shown in 
D) shows immunolabeling of proximal processes of amacrine cells (marked with an 
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asterisk) in INL and positive neuronal processes in a dense plexus in IPL. D: DIC image 
corresponding to section C. scale bar: 13 M 
 
Fig. 3 Verification of OATP1A2 and OATP2B1 expression on Western blots of 
human retina homogenates 
Retina homogenates were prepared and processed for Western blotting as 
described in Materials and Methods. The blots were probed with OATP1A2 antibody 
(lane 1), OATP1A2 antibody preabsorbed with immunizing peptide (lane 2), OATP2B1 
antibody (lane 3) and OATP2B1 antibody preabsorbed with immunizing peptide (lane 4). 
 
Fig. 4 Uptake of substance P and vasoactive intestinal peptide into OATP1A2- 
and OATP2B1-expressing Xenopus laevis oocytes 
OATPs were expressed in X. laevis oocytes and uptakes of either 0.2 M 
substance P (SP), 2.5 nM vasoactive intestinal peptide (VIP), 1.5 pM somatostatin (SOM) 
or 47 nM neuropeptide Y (NPY) were determined over 30 min as described in Materials 
and Methods. Values are given as means  SD uptakes determined in of 12 to 15 oocytes 
incubated in 100 mM NaCl or 100 mM choline chloride containing medium. * p<0.5, ** 
p< 0.01 
Fig. 5 Kinetics of OATP1A2- and OATP2B1-mediated uptake of substance P 
(SP) and vasoactive intestinal peptide (VIP) in X. laevis oocytes 
OATPs were expressed in X. laevis oocytes and uptake of increasing 
concentrations of SP and VIP into X. laevis oocytes was determined over 30 min as 
described in Materials and Methods. Uptake values are given as the difference between 
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OATP expressing oocytes and control (water injected) oocytes. Values are given as 
means  SD of uptakes into 12 to 15 oocytes incubated in 100 mM NaCl containing 
medium. The curves were fitted by nonlinear regression analysis (GraphPad Prism, San 
Diego CA) to the Michaelis-Menten equation. 
Fig. 6 Colocalization of OATP1A1 and OATP2B1 and substance P (SP) 
A: OATP1A2 immunofluorescence is depicted in red (left column) and SP 
immunofluorescence is in green (middle column). The right column shows an extensive 
colocalization (yellow) of OATP1A2 and its substrate SP in amacrine cells (marked with 
arrows) of INL and neurites (marked with arrows) of IPL and GCL. scale bar: 18 M B: 
OATP2B1 immunofluorescence is coloured red (left column) and SP 
immunofluorescence is shown in green (middle column). The right column shows 
colocalization (yellow) of OATP2B1 and its substrate SP in neuronal processes (marked 
with arrows) of IPL. scale bar: 18 M 
Fig. 7 Colocalization of OATP1A2 and OATP2B1 and vasoactive intestinal 
peptide (VIP) 
A: OATP1A2 immunofluorescence is shown in red (left column) and VIP 
immunofluorescence is in green (middle column). The right column shows an extensive 
colocalization (yellow) of the OATP1A2 and its VIP substrate in small cells and neurites 
in GCL and colocalization OATP1A2 and its substrate in IPL and INL. scale bar: 10 M 
B: OATP2B1 immunofluorescence is given in red (left column) and SP 
immunofluorescence is in green (middle column). The right column shows colocalization 
(yellow) of OATP2B1 and its substrate VIP in neuronal processes in INL and IPL. scale 
bar: 13 M (upper), 13 M (bottom) 
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Fig. 8 Immunolocalization of OATP1A2 in human frontal cortex 
A: Overview of OATP1A2 immunolabelling showing scattered imunoreactivity in 
various layers. scale bar: 400 M B: OATP1A2 immunoreactivity is absent in the 
negative control after preabsorption of the antibody with the immunizing peptide. C: 
Higher magnification demonstrating a clear OATP1A2 labeling in cell somas and 
neuronal processes. scale bar: 43 M 
Fig. 9 Immunolocalization of OATP1A2 in human hippocampal formation 
A: Composite of sections across hippocampal areas showing an overview of 
OATP1A2 immunolabelling with intense labelling from CA1 to CA3. scale bar: 700 M 
B: The close-up of the CA-2 region shows OATP1A2 immunopositivity in numerous 
pyramidal neurons and their processes. C: OATP1A2 immunoreactivity is predominantly 
present in the plasma membrane of granule cell somas and neuronal processes in the 
stratum moleculare of the dentate gyrus (SM). scale bar: 37 M 
Fig. 10 Immunolocalization of OATP2B1 in human frontal cortex and in 
hippocampus 
A: OATP2B1 immunoreactivity in brain capillaries of human frontal cortex 
(negative control in insert). scale bar: 15 M B: OATP2B1 immunoreactivity in brain 
capillaries of human hippocampus. scale bar: 150 M C: A close-up of B confirming the 
exclusive expression of OATP2B1 in the capillary endothelium. scale bar: 43 M 
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